内脏转移前列腺癌患者全身治疗疗效:系统评价、Meta分析与网状Meta分析
本系统评价与网状Meta分析纳入12项随机对照试验,评估内脏转移对转移性激素敏感性前列腺癌和转移性去势抵抗性前列腺癌患者联合全身治疗疗效的影响。结果显示,无论有无内脏转移,新型全身治疗均改善总生存;作者认为需进一步设计良好的研究详细记录内脏转移部位和数量。
要点
- 转移性激素敏感性前列腺癌中,标准治疗加雄激素受体信号抑制剂改善总生存:有内脏转移者汇总HR 0.77(95%CI 0.64-0.94),无内脏转移者汇总HR 0.66(95%CI 0.60-0.72)。
- 多西他赛治疗后转移性去势抵抗性前列腺癌中,雄激素剥夺治疗加雄激素受体信号抑制剂改善总生存:有内脏转移者汇总HR 0.79(95%CI 0.63-0.98),无内脏转移者汇总HR 0.63(95%CI 0.55-0.72)。
- 转移性激素敏感性前列腺癌治疗排名中,达罗他胺联合多西他赛和雄激素剥夺治疗改善总生存的可能性最高,无论有无内脏转移。
核心结论
- 尽管有内脏转移的转移性激素敏感性前列腺癌和转移性去势抵抗性前列腺癌临床行为更具侵袭性、病程轨迹更差,新型全身治疗在有和无内脏转移患者中的有效性相似。
- 作者认为,需进一步设计良好的研究详细记录内脏转移部位和数量,以丰富临床决策。
研究设计与样本
- 系统评价、Meta分析与网状Meta分析,检索三个数据库(2022年7月),纳入分析转移性前列腺癌患者联合全身治疗(雄激素受体信号抑制剂和/或多西他赛联合雄激素剥夺治疗)对比标准治疗的随机对照试验。
- 共12项随机对照试验纳入系统评价,8项纳入Meta分析/网状Meta分析。
- 主要结局为总生存,次要结局为无进展生存;采用固定效应模型进行正式Meta分析,采用随机效应模型进行网状Meta分析。
- 遵循PRISMA和AMSTAR指南。
主要发现
- 转移性激素敏感性前列腺癌中,标准治疗加雄激素受体信号抑制剂改善总生存:有内脏转移者汇总HR 0.77(95%CI 0.64-0.94),无内脏转移者汇总HR 0.66(95%CI 0.60-0.72);跨试验和试验内方法均无差异(P=.13和P=.06)。
- 转移性激素敏感性前列腺癌中,雄激素受体信号抑制剂联合雄激素剥夺治疗的无进展生存获益在有内脏转移患者中较低,跨试验方法P=.03,试验内方法P=.14未达统计学显著。
- 转移性激素敏感性前列腺癌治疗排名显示,达罗他胺联合多西他赛和雄激素剥夺治疗改善总生存的可能性最高,无论有无内脏转移。
- 多西他赛治疗后转移性去势抵抗性前列腺癌中,雄激素剥夺治疗加雄激素受体信号抑制剂显著改善总生存:有内脏转移者汇总HR 0.79(95%CI 0.63-0.98),无内脏转移者汇总HR 0.63(95%CI 0.55-0.72)。
- 无随机对照试验报告按肺转移 vs 肝转移分层的肿瘤学结局差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 无随机对照试验报告按肺转移 vs 肝转移分层的肿瘤学结局差异。
- 作者认为需进一步设计良好的研究详细记录内脏转移部位和数量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: There are limited pooled data showing the impact of visceral metastasis on oncologic outcomes in metastatic prostate cancer patients treated with combination systemic therapies. We aimed to analyze and compare the efficacy of combination systemic therapies in metastatic hormone-sensitive prostate cancer and metastatic castration-resistant prostate cancer with or without visceral metastasis. MATERIALS AND METHODS: Three databases were queried in July 2022 for randomized, controlled trials analyzing metastatic prostate cancer patients treated with combination systemic therapy (androgen receptor signaling inhibitor and/or docetaxel plus androgen deprivation therapy) to standard of care. We analyzed the association between presence of visceral metastases and efficacy of systemic therapies in metastatic hormone-sensitive prostate cancer and metastatic castration-resistant prostate cancer patients. The main and secondary outcomes of interest were overall survival and progression-free survival, respectively. Formal meta-analysis using fixed-effect model and network meta-analysis using random-effect model were conducted. We followed PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) and AMSTAR (A MeaSurement Tool to Assess systematic Reviews) guidelines. RESULTS: Overall, 12 and 8 randomized, controlled trials were included for systematic review and meta-analyses/network meta-analyses, respectively. In metastatic hormone-sensitive prostate cancer patients, adding androgen receptor signaling inhibitor to standard of care improved overall survival in patients with visceral metastasis (pooled HR: 0.77, 95% CI: 0.64-0.94) as well as in those without (pooled HR: 0.66, 95% CI: 0.60-0.72; no differences in both across- and within-trial approach; P = .13 and P = .06, respectively). On the other hand, the progression-free survival benefit from androgen receptor signaling inhibitor + androgen deprivation therapy was significantly lower in patients with visceral metastasis using across-trial approach (P = .03), while it did not reach statistical significance using within-trial approach (P = .14). Analysis of treatment ranking in metastatic hormone-sensitive prostate cancer showed that darolutamide + docetaxel + androgen deprivation therapy had the highest likelihood of improved overall survival irrespective of visceral metastasis. In post-docetaxel metastatic castration-resistant prostate cancer patients, adding androgen receptor signaling inhibitor to androgen deprivation therapy significantly improved overall survival in both patients with visceral metastasis (pooled HR: 0.79, 95% CI: 0.63-0.98) and those without (pooled HR: 0.63, 95% CI: 0.55-0.72). No randomized, controlled trials reported the differential oncologic outcomes stratified by lung vs liver metastases. CONCLUSIONS: Despite aggressive clinical behavior and worse trajectory of metastatic hormone-sensitive prostate cancer and metastatic castration-resistant prostate cancer with visceral metastasis, the effectiveness of novel systemic therapies is similar in both metastatic hormone-sensitive prostate cancer and metastatic castration-resistant prostate cancer patients with and without visceral metastasis. Further well-designed studies with detailed visceral metastatic sites and number will enrich the clinical decision-making.
引用
- Yanagisawa T, Rajwa P, Kawada T, et al. Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis. J Urol. 2023. PMID: 37339479. doi:10.1097/JU.0000000000003594
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。